Neumora Therapeutics (NMRA) Cash from Financing Activities (2022 - 2026)

Neumora Therapeutics has reported Cash from Financing Activities for 5 years, with the latest figure at $10.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to $10.9 million; the trailing twelve-month figure through Mar 2026 stood at $88.0 million (up 345.21% YoY), and the FY2025 full-year result was $77.1 million, up 256.84% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $10.9 million, down from $58.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $232.0 million in Q3 2023, with the low at -$481000.0 in Q4 2023.
• Average Cash from Financing Activities over 5 years is $28.3 million, with a median of $2.7 million recorded in 2024.
• Year-over-year, Cash from Financing Activities surged 3337.63% in 2024 and sank 108.88% in 2025.
• Tracing NMRA's Cash from Financing Activities over 5 years: stood at $26.8 million in 2022, then slumped by 101.79% to -$481000.0 in 2023, then surged by 3337.63% to $15.6 million in 2024, then jumped by 277.37% to $58.8 million in 2025, then sank by 81.5% to $10.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $10.9 million (Q1 2026), $58.8 million (Q4 2025), and -$136000.0 (Q3 2025), per Business Quant data.

Peer Comparison